Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus.

Trial Profile

Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2013

At a glance

  • Drugs Oxyntomodulin (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Jul 2013 Primary endpoint added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top